Tag: Relapsed Refractory Multiple Myeloma
-
AbbVie’s Etentamig Cuts Progression or Death Risk by 60% in Phase 3 Multiple Myeloma Trial
AbbVie’s etentamig met both primary endpoints in the Phase 3 CERVINO trial, achieving a 74.0% objective response rate and reducing the risk of progression or death by 60% versus standard available therapies.
-
Johnson & Johnson Wins EU Approval for Tecvayli Plus Darzalex in Multiple Myeloma
The European Commission approved Tecvayli plus Darzalex for adults with relapsed or refractory multiple myeloma after at least one prior therapy, supported by Phase 3 MajesTEC-3 data showing an 83% reduction in the risk of progression or death versus DPd or DVd.